BPS804, UX143 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
274骨形成不全症1

274. 骨形成不全症


臨床試験数 : 91 薬物数 : 101 - (DrugBank : 20) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 48
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006597-23-FR
(EUCTR)
04/05/2022A study to test product setrusumab in subjects with brittle bone syndrome.A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta. Osteogenesis imperfecta (OI)
MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Setrusumab
Product Code: BPS804, UX143
INN or Proposed INN: SETRUSUMAB
Other descriptive name: UX143, BPS804
Ultragenyx Pharmaceutical Inc.NULLNAFemale: yes
Male: yes
231Phase 2;Phase 3United States;France;Canada;Argentina;Denmark;Australia;Germany;United Kingdom;Italy